Mark Chapman
Long only, contrarian, event-driven

Antares Pharma: Recent Sell-Off Provides Great Entry Point

Antares Pharma (NASDAQ:ATRS) announced 4Q2013 and FY2013 results before the market open on March 13, and investors weren't impressed. The company reported 4Q2013 loss of $0.04 per share on revenue of $4.7m, which was pretty much in-line with my expectations, but the stock ended up closing down over 5.6% on twice the average daily volume. I don't think the drop in the stock price should be attributed to the actual results, however, but instead on the continued slow development of the Teva (NYSE:TEVA) programs and lack of details provided on the conference call. Although we may not have seen capitulation yet as retail investors throw in the towel, I do think we are nearing a bottom...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details